Tags

Type your tag names separated by a space and hit enter

Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Horm Metab Res. 2009 Feb; 41(2):104-8.HM

Abstract

Endothelial dysfunction (ED) has been suggested as a possible causal link between postprandial hyperglycemia and cardiovascular events in patients with type 2 diabetes. Recent trials demonstrated a reduction of cardiovascular events by treatment with alpha-glucosidase inhibitor acarbose - a drug which mainly reduces postprandial glucose excursions. We were interested to know whether patients with newly diagnosed type 2 diabetes showed postprandial ED and if so whether acarbose was able to improve this condition. Forearm blood flow (FBF) measurements for assessment of ED were performed in the fasting and postprandial state in 20 newly diagnosed type 2 diabetic patients and 10 healthy control subjects. After baseline examination, patients were randomly assigned to a 20-week treatment of acarbose 100 mg t.i.d or matching placebo, thereafter FBF measurements were repeated. FBF of patients in the fasting state was significantly impaired compared to healthy control subjects (max. FBF 5.3+/-0.7 vs. 8.0+/-0.9 ml/100 ml, p<0.02) and did not change in the postprandial state (max. FBF 5.6+/-0.7 ml/100 ml). In contrast, healthy controls showed a significant improvement of FBF in the postprandial state (11.5+/-1.2 ml/100 ml), which is compatible with postprandial ED in the group of patients. Twenty weeks of acarbose treatment did not affect either fasting or postprandial FBF in patients. Early type 2 diabetes is a state of both fasting and postprandial ED, which is not sensitive to acarbose treatment. Protective cardiovascular effects of acarbose might involve other mechanisms.

Authors+Show Affiliations

Department of Medicine, Technical University of Dresden, Dresden, Germany. frankpistrosch@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19061152

Citation

Pistrosch, F, et al. "Effects of the Alpha Glucosidase Inhibitor Acarbose On Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes." Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 41, no. 2, 2009, pp. 104-8.
Pistrosch F, Schaper F, Passauer J, et al. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. Horm Metab Res. 2009;41(2):104-8.
Pistrosch, F., Schaper, F., Passauer, J., Koehler, C., Bornstein, S. R., & Hanefeld, M. (2009). Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 41(2), 104-8. https://doi.org/10.1055/s-0028-1103276
Pistrosch F, et al. Effects of the Alpha Glucosidase Inhibitor Acarbose On Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes. Horm Metab Res. 2009;41(2):104-8. PubMed PMID: 19061152.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. AU - Pistrosch,F, AU - Schaper,F, AU - Passauer,J, AU - Koehler,C, AU - Bornstein,S R, AU - Hanefeld,M, Y1 - 2008/12/05/ PY - 2008/12/9/pubmed PY - 2009/4/7/medline PY - 2008/12/9/entrez SP - 104 EP - 8 JF - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme JO - Horm Metab Res VL - 41 IS - 2 N2 - Endothelial dysfunction (ED) has been suggested as a possible causal link between postprandial hyperglycemia and cardiovascular events in patients with type 2 diabetes. Recent trials demonstrated a reduction of cardiovascular events by treatment with alpha-glucosidase inhibitor acarbose - a drug which mainly reduces postprandial glucose excursions. We were interested to know whether patients with newly diagnosed type 2 diabetes showed postprandial ED and if so whether acarbose was able to improve this condition. Forearm blood flow (FBF) measurements for assessment of ED were performed in the fasting and postprandial state in 20 newly diagnosed type 2 diabetic patients and 10 healthy control subjects. After baseline examination, patients were randomly assigned to a 20-week treatment of acarbose 100 mg t.i.d or matching placebo, thereafter FBF measurements were repeated. FBF of patients in the fasting state was significantly impaired compared to healthy control subjects (max. FBF 5.3+/-0.7 vs. 8.0+/-0.9 ml/100 ml, p<0.02) and did not change in the postprandial state (max. FBF 5.6+/-0.7 ml/100 ml). In contrast, healthy controls showed a significant improvement of FBF in the postprandial state (11.5+/-1.2 ml/100 ml), which is compatible with postprandial ED in the group of patients. Twenty weeks of acarbose treatment did not affect either fasting or postprandial FBF in patients. Early type 2 diabetes is a state of both fasting and postprandial ED, which is not sensitive to acarbose treatment. Protective cardiovascular effects of acarbose might involve other mechanisms. SN - 1439-4286 UR - https://www.unboundmedicine.com/medline/citation/19061152/Effects_of_the_alpha_glucosidase_inhibitor_acarbose_on_endothelial_function_after_a_mixed_meal_in_newly_diagnosed_type_2_diabetes_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0028-1103276 DB - PRIME DP - Unbound Medicine ER -